Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malaria, Falciparum | 4 | 2025 | 119 | 1.850 |
Why?
|
| Plasmodium falciparum | 2 | 2025 | 135 | 1.480 |
Why?
|
| Killer Cells, Natural | 3 | 2021 | 215 | 1.330 |
Why?
|
| Burkitt Lymphoma | 5 | 2023 | 58 | 1.320 |
Why?
|
| Antigens, Protozoan | 1 | 2025 | 41 | 0.960 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2023 | 92 | 0.910 |
Why?
|
| CD56 Antigen | 2 | 2020 | 15 | 0.780 |
Why?
|
| Cytomegalovirus Infections | 3 | 2018 | 70 | 0.740 |
Why?
|
| Cytomegalovirus | 3 | 2018 | 89 | 0.730 |
Why?
|
| Graft Rejection | 3 | 2018 | 264 | 0.690 |
Why?
|
| Receptors, IgG | 1 | 2020 | 36 | 0.680 |
Why?
|
| Immune System | 1 | 2019 | 129 | 0.590 |
Why?
|
| Kenya | 5 | 2025 | 83 | 0.530 |
Why?
|
| B7-H1 Antigen | 1 | 2016 | 53 | 0.520 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 191 | 0.500 |
Why?
|
| Malaria Vaccines | 2 | 2025 | 26 | 0.400 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 21 | 0.390 |
Why?
|
| Sarcoma, Kaposi | 2 | 2023 | 17 | 0.380 |
Why?
|
| Child | 6 | 2025 | 4313 | 0.360 |
Why?
|
| Herpesvirus 4, Human | 5 | 2023 | 183 | 0.330 |
Why?
|
| Child, Preschool | 4 | 2025 | 1839 | 0.330 |
Why?
|
| Kidney Transplantation | 3 | 2018 | 268 | 0.310 |
Why?
|
| Seroepidemiologic Studies | 4 | 2023 | 48 | 0.280 |
Why?
|
| Tissue Donors | 2 | 2018 | 134 | 0.270 |
Why?
|
| Antibodies, Protozoan | 1 | 2025 | 48 | 0.240 |
Why?
|
| Humans | 19 | 2025 | 60081 | 0.230 |
Why?
|
| Graft Survival | 2 | 2016 | 280 | 0.200 |
Why?
|
| Microbiota | 1 | 2023 | 104 | 0.190 |
Why?
|
| Receptors, KIR | 1 | 2021 | 3 | 0.190 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2020 | 5 | 0.170 |
Why?
|
| Herpesviridae Infections | 1 | 2020 | 28 | 0.170 |
Why?
|
| Herpesviridae | 1 | 2020 | 14 | 0.170 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 202 | 0.170 |
Why?
|
| Adolescent | 3 | 2025 | 5944 | 0.160 |
Why?
|
| Antimalarials | 1 | 2019 | 68 | 0.160 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 679 | 0.150 |
Why?
|
| RNA, Viral | 1 | 2019 | 265 | 0.150 |
Why?
|
| Flow Cytometry | 1 | 2020 | 638 | 0.150 |
Why?
|
| Genes, MHC Class I | 1 | 2018 | 28 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2020 | 235 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 170 | 0.140 |
Why?
|
| Antibodies, Viral | 3 | 2024 | 302 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 240 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2020 | 744 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2021 | 1298 | 0.130 |
Why?
|
| Adult | 3 | 2025 | 15972 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2016 | 31 | 0.130 |
Why?
|
| Vaccination | 1 | 2019 | 342 | 0.130 |
Why?
|
| Lung Transplantation | 1 | 2016 | 48 | 0.130 |
Why?
|
| Prognosis | 2 | 2019 | 1591 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2016 | 257 | 0.130 |
Why?
|
| Female | 6 | 2025 | 31226 | 0.130 |
Why?
|
| Male | 5 | 2025 | 27951 | 0.120 |
Why?
|
| Young Adult | 1 | 2025 | 4398 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2019 | 617 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1064 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 651 | 0.110 |
Why?
|
| Infant | 3 | 2023 | 1522 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2021 | 6147 | 0.090 |
Why?
|
| Alleles | 2 | 2023 | 417 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 2507 | 0.090 |
Why?
|
| Animals | 4 | 2023 | 19739 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2010 | 159 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 304 | 0.080 |
Why?
|
| Middle Aged | 3 | 2024 | 16542 | 0.070 |
Why?
|
| Saliva | 1 | 2024 | 96 | 0.060 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2023 | 5 | 0.060 |
Why?
|
| Feeding Methods | 1 | 2023 | 9 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2023 | 66 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2023 | 34 | 0.050 |
Why?
|
| Parturition | 1 | 2023 | 54 | 0.050 |
Why?
|
| Rituximab | 1 | 2023 | 82 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2022 | 35 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 94 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2022 | 59 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2023 | 90 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2023 | 448 | 0.050 |
Why?
|
| Endemic Diseases | 1 | 2021 | 14 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2022 | 178 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 450 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 280 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 229 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 377 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2019 | 47 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 1100 | 0.040 |
Why?
|
| Coinfection | 1 | 2020 | 44 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 628 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 260 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 1387 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 391 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 10317 | 0.040 |
Why?
|
| Massachusetts | 1 | 2024 | 2119 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 621 | 0.040 |
Why?
|
| Viral Matrix Proteins | 1 | 2018 | 52 | 0.040 |
Why?
|
| Computational Biology | 1 | 2019 | 337 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2018 | 133 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 169 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2018 | 212 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2018 | 353 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1527 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2361 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 2074 | 0.030 |
Why?
|
| Virus Activation | 1 | 2010 | 24 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 236 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 13596 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2010 | 317 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 5266 | 0.010 |
Why?
|